# Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD

> **NCT05407636** · PHASE3 · RECRUITING · sponsor: **AbbVie** · enrollment: 714 (estimated)

## Conditions studied

- AMD
- nAMD
- Wet Age-related Macular Degeneration
- wAMD
- WetAMD
- CNV

## Interventions

- **GENETIC:** ABBV-RGX-314 Dose 1
- **GENETIC:** ABBV-RGX-314 Dose 2
- **BIOLOGICAL:** Aflibercept (EYLEA®)

## Key facts

- **NCT ID:** NCT05407636
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-01-13
- **Primary completion:** 2026-10
- **Final completion:** 2027-11
- **Target enrollment:** 714 (ESTIMATED)
- **Last updated:** 2026-04-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05407636

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05407636, "Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD". Retrieved via AI Analytics 2026-08-12 from https://api.ai-analytics.org/clinical/NCT05407636. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*